Pancreatic Cancer Research

ResearcherUniversity of MichiganActive in the last 2 years

Filip Bednar

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-5193-9817; OpenAlex author ID A5057539744; NIH RePORTER profile ID 10594602. Sources: OpenAlex.

Their work

Papers
36 (first author 2, last author 2)
Trials
0
Grants
1
Labs led
1
Collaborators
92
Papers, trials and grants by year

2011: 1 paper · 2012: 2 papers · 2013: 2 papers · 2014: 1 paper · 2015: 1 paper · 2016: none · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: 4 papers · 2021: 6 papers · 2022: 2 papers · 2023: 3 papers · 2024: 3 papers · 2025: 4 papers · 2026: 5 papers, 1 grant

Papers 36

  1. Wilms Tumor 1-Expressing Stromal Cells Promote Pancreatic Cancer Progression. Co-author DOI 10.1158/0008-5472.can-25-1014↗
  2. Longitudinal Analysis of Matched Patient Biospecimens Reveals Neural Reprogramming of Cancer-Associated Fibroblasts Following Chemotherapy in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-26-0823↗
  3. Aryl Hydrocarbon Receptor Ligands Drive Pancreatic Cancer Initiation and Progression through Protumorigenic T-cell Polarization. Co-author DOI 10.1158/2159-8290.cd-25-0377↗
  4. Asynchronous Evolution of Epithelium and Stroma Differentiates Precursor Lesions from Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-25-2001↗
  5. Targeting CCR1 Remodels the Tumor Microenvironment and Relieves Immunosuppression in Pancreatic Cancer. Co-author DOI 10.1158/2326-6066.cir-25-1300↗
  6. Primary and metastatic cellular landscapes in human pancreatic cancer. Co-author DOI 10.1016/j.isci.2025.113012↗
  7. Mouse Models for Pancreatic Ductal Adenocarcinoma are Affected by the cre-driver Used to Promote KRAS G12D Activation. Last author DOI 10.1016/j.jcmgh.2024.101428↗
  8. DUSP6 is upregulated in metastasis and influences migration and metabolism in pancreatic cancer cells. Co-author DOI 10.1038/s41598-025-12967-8↗
  9. Aspartate Transaminases Are Dispensable for Pancreatic Development and Pancreatic Cancer Progression Co-author DOI 10.64898/2025.12.17.694916↗
  10. From Inception to Malignancy: the Co-evolution of Pancreatic Cancer and Its Immunosuppressive Microenvironment. Co-author DOI 10.1158/0008-5472.can-24-2732↗
  11. KRT17high/CXCL8+ Tumor Cells Display Both Classical and Basal Features and Regulate Myeloid Infiltration in the Pancreatic Cancer Microenvironment. Co-author DOI 10.1158/1078-0432.ccr-23-1421↗
  12. Notch Signaling Regulates Immunosuppressive Tumor-Associated Macrophage Function in Pancreatic Cancer. Last author DOI 10.1158/2326-6066.cir-23-0037↗
  13. Predictors of Acute and Late Toxicity in Patients Receiving Chemoradiation for Unresectable Pancreatic Cancer. Co-author DOI 10.1016/j.adro.2023.101266↗
  14. Calligraphy tool offers clues to the origin of pancreatic cancer. Co-author DOI 10.1038/d41586-023-02518-4↗
  15. Arginase 1 is a key driver of immune suppression in pancreatic cancer. Co-author DOI 10.7554/elife.80721↗
  16. Clinical Staging Uncertainty and Treatment Sequencing in Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000005317↗
  17. Combinatorial Gli activity directs immune infiltration and tumor growth in pancreatic cancer. Co-author DOI 10.1371/journal.pgen.1010315↗
  18. Immunotherapy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jso.26312↗
  19. The Gustatory Sensory G-Protein GNAT3 Suppresses Pancreatic Cancer Progression in Mice. Co-author DOI 10.1016/j.jcmgh.2020.08.011↗
  20. Association of Adjuvant Radiotherapy With Survival After Margin-negative Resection of Pancreatic Ductal Adenocarcinoma: A Propensity-matched National Cancer Da… Co-author DOI 10.1097/sla.0000000000003242↗
  21. Inhibition of Hedgehog Signaling Alters Fibroblast Composition in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-3715↗
  22. Pancreatic cancer is marked by complement-high blood monocytes and tumor-associated macrophages. Co-author DOI 10.26508/lsa.202000935↗
  23. Clinical Utility of Epigenetic Changes in Pancreatic Adenocarcinoma. First author DOI 10.3390/epigenomes5040020↗
  24. Context-Dependent Immune Responses Explain Pancreatic Cancer Immunoresistance. Co-author DOI 10.1016/j.ccell.2020.02.010↗
  25. Differential Contribution of Pancreatic Fibroblast Subsets to the Pancreatic Cancer Stroma. Co-author DOI 10.1016/j.jcmgh.2020.05.004↗
  26. Multimodal Mapping of the Tumor and Peripheral Blood Immune Landscape in Human Pancreatic Cancer. Co-author DOI 10.1038/s43018-020-00121-4↗
  27. Chemotherapy and Tumor Evolution Shape Pancreatic Cancer Recurrence after Resection. Co-author DOI 10.1158/2159-8290.cd-20-0359↗
  28. Metabolism and epigenetics of pancreatic cancer stem cells. Co-author DOI 10.1016/j.semcancer.2018.09.008↗
  29. Analysis of Predictors of Resection and Survival in Locally Advanced Stage III Pancreatic Cancer: Does the Nature of Chemotherapy Regimen Influence Outcomes? Co-author DOI 10.1245/s10434-016-5707-0↗
  30. Bmi1 is required for the initiation of pancreatic cancer through an Ink4a-independent mechanism. Co-author DOI 10.1093/carcin/bgv058↗
  31. The Notch pathway is important in maintaining the cancer stem cell population in pancreatic cancer. Co-author DOI 10.1371/journal.pone.0091983↗
  32. Interleukin-6 is required for pancreatic cancer progression by promoting MAPK signaling activation and oxidative stress resistance. Co-author DOI 10.1158/0008-5472.can-13-1558-t↗
  33. Bmi1 enhances tumorigenicity and cancer stem cell function in pancreatic adenocarcinoma. Co-author DOI 10.1371/journal.pone.0055820↗
  34. Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. First author DOI 10.1172/jci59227↗
  35. Metastatic pancreatic cancer is dependent on oncogenic Kras in mice. Co-author DOI 10.1371/journal.pone.0049707↗
  36. Pancreatic cancer stem cell biology and its therapeutic implications. Co-author DOI 10.1007/s00535-011-0494-7↗

Grants 1

  1. Dissecting the role of Notch signaling in the pancreatic cancer microenvironment. R01CA271510↗

Closest collaborators

The 25 strongest of 92 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Marina Pasca di Magliano · 26 shared papers, 1 shared grant, 2012–2026 · strength 5.49
  2. Timothy L. Frankel · 15 shared papers, 2019–2026 · strength 2.47
  3. Eileen S. Carpenter · 13 shared papers, 2020–2026 · strength 2.10
  4. Costas Andreas Lyssiotis · 10 shared papers, 2019–2026 · strength 1.54
  5. Padma Kadiyala · 7 shared papers, 2023–2026 · strength 1.30
  6. Katelyn L. Donahue · 8 shared papers, 2020–2026 · strength 1.22
  7. Jiaqi Shi · 6 shared papers, 2024–2026 · strength 1.20
  8. Ahmed M. Elhossiny · 6 shared papers, 2024–2026 · strength 1.16
  9. Yaqing Zhang · 6 shared papers, 2020–2026 · strength 1.14
  10. Vaibhav Sahai · 7 shared papers, 2020–2026 · strength 1.02
  11. Nina G. Steele · 8 shared papers, 2020–2025 · strength 0.99
  12. Howard C. Crawford · 8 shared papers, 2020–2025 · strength 0.92
  13. Samantha B. Kemp · 7 shared papers, 2020–2025 · strength 0.86
  14. Emily L. Lasse Opsahl · 4 shared papers, 2025–2026 · strength 0.85
  15. Zeribe C. Nwosu · 6 shared papers, 2021–2026 · strength 0.77
  16. Yaqing Zhang · 9 shared papers, 2012–2023 · strength 0.69
  17. Rosa Elena Menjivar · 4 shared papers, 2022–2026 · strength 0.64
  18. Joyce K. Thompson · 3 shared papers, 2019–2025 · strength 0.62
  19. Wei Yan · 3 shared papers, 2024–2026 · strength 0.61
  20. Benjamin Allen · 5 shared papers, 2020–2025 · strength 0.57
  21. Valerie Gunchick · 4 shared papers, 2020–2025 · strength 0.49
  22. Wenting Du · 3 shared papers, 2023–2024 · strength 0.45
  23. Mariana T. Ruckert · 2 shared papers, 2025–2026 · strength 0.44
  24. Brian D. Griffith · 2 shared papers, 2026 · strength 0.43
  25. Dominik Awad · 2 shared papers, 2025–2026 · strength 0.39

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.